Prostate-specific membrane antigen targeting positron emission tomography (PSMA-PET) in prostate cancer: PSMA-RADS classification and PROMISE criterias

被引：0
|
作者：
Robin, P. [1 ,2 ,5 ]
Palard-Novello, X. [3 ,4 ]
Bailly, C.
机构：
[1] Ctr Hosp Univ Brest, Serv Med Nucl, 2 Ave Foch, F-29269 Brest, France
[2] Univ Brest, CHU Brest, UMR 1304, Inserm, Brest, France
[3] Univ Rennes, CLCC Eugene Marquis, INSERM, LTSI UMR 1099, Ave Bataille Flandres Dunkerque, F-35042 Rennes, France
[4] Ctr Hosp Univ Nantes, Serv Med Nucl, Nantes, France
[5] Univ Brest, Ctr Hosp & Univ Brest, Inserm, UMR 1304,CHRU Brest,GETBO,Serv Med Nucl, 2 Ave Foch, F-29609 Brest, France
来源：
MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE | 2023年 / 47卷 / 05期
关键词：
Positron emission tomography; Prostate specific membrane antigen; receptor; Prostate cancer; Classifications; VERSION; PEARLS; EANM;
D O I：
10.1016/j.mednuc.2023.07.005
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
Prostate-specific membrane antigen targeting positron emission tomography (PSMA-PET) is nowadays widely used for the management of patients with prostate cancer during natural history of the disease. PSMA is not specific to prostate tissue, many benign and malignant diseases unrelated to prostate cancer are frequently found on PSMA-PET examinations, leading to false positives results and potentially to inadequate patient management. Various interpretation criteria have been proposed within classifications in order to standardize and homogenize PSMA-PET interpretation. This article describes, on the one hand the PSMA-RADS classification, and on the other hand the PROMISE criteria. (c) 2023 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：270 / 275
页数：6
相关论文
共 50 条
  • [21] Prognostic impact of prostate-specific membrane antigen positron emission tomography (PSMA PET) staging for clinically node-positive prostate cancer
    Leow, Boon Yang Jerome
    Eade, Thomas
    Hruby, George
    Lieng, Hester
    Hsiao, Edward
    Brown, Chris
    Kneebone, Andrew
    JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 2024, 68 (06) : 721 - 728
  • [22] Reliability and practicability of PSMA-RADS 1.0 for structured reporting of PSMA-PET/CT scans in prostate cancer patients
    Freba Grawe
    Franziska Blom
    Michael Winkelmann
    Caroline Burgard
    Christine Schmid-Tannwald
    Lena M. Unterrainer
    Gabriel T. Sheikh
    Paulo L. Pfitzinger
    Philipp Kazmierczak
    Clemens C. Cyran
    Jens Ricke
    Christian G. Stief
    Peter Bartenstein
    Johannes Ruebenthaler
    Matthias P. Fabritius
    Thomas Geyer
    European Radiology, 2024, 34 : 1157 - 1166
  • [23] Reliability and practicability of PSMA-RADS 1.0 for structured reporting of PSMA-PET/CT scans in prostate cancer patients
    Grawe, Freba
    Blom, Franziska
    Winkelmann, Michael
    Burgard, Caroline
    Schmid-Tannwald, Christine
    Unterrainer, Lena M.
    Sheikh, Gabriel T.
    Pfitzinger, Paulo L.
    Kazmierczak, Philipp
    Cyran, Clemens C.
    Ricke, Jens
    Stief, Christian G.
    Bartenstein, Peter
    Ruebenthaler, Johannes
    Fabritius, Matthias P.
    Geyer, Thomas
    EUROPEAN RADIOLOGY, 2023, 34 (2) : 1157 - 1166
  • [24] Interobserver and intraobserver agreement on prostate-specific membrane antigen PET/CT images according to the miTNM and PSMA-RADS criteria
    Demirci, Emre
    Akyel, Resit
    Caner, Biray
    Alan-Selcuk, Nalan
    Guven-Mese, Sermin
    Ocak, Meltem
    Kabasakal, Levent
    NUCLEAR MEDICINE COMMUNICATIONS, 2020, 41 (08) : 759 - 767
  • [25] Imaging with prostate-specific membrane antigen (PSMA) in prostate cancer
    Feneley, MR
    Jan, H
    Granowska, M
    Mather, SJ
    Ellison, D
    Glass, J
    Coptcoat, M
    Kirby, RS
    Ogden, C
    Oliver, RTD
    Badenoch, DF
    Chinegwundoh, FI
    Nargund, VH
    Paris, AMI
    Britton, KE
    PROSTATE CANCER AND PROSTATIC DISEASES, 2000, 3 (01) : 47 - 52
  • [26] Imaging with prostate-specific membrane antigen (PSMA) in prostate cancer
    MR Feneley
    H Jan
    M Granowska
    SJ Mather
    D Ellison
    J Glass
    M Coptcoat
    RS Kirby
    C Ogden
    RTD Oliver
    DF Badenoch
    FI Chinegwundoh
    VH Nargund
    AMI Paris
    KE Britton
    Prostate Cancer and Prostatic Diseases, 2000, 3 : 47 - 52
  • [27] Prostate-Specific Membrane Antigen (PSMA) PET: A Counterpart to Prostate MRI
    Chen, Christine
    Margolis, Daniel
    SEMINARS IN ROENTGENOLOGY, 2021, 56 (04) : 376 - 383
  • [28] COST EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) FOR THE EVALUATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER IN THE UNITED STATES HEALTHCARE SYSTEM
    Kunst, Natalia
    Long, Jessica B.
    Westvold, Sarah
    Sprenkle, Preston
    Rabil, Maximilian
    Ghaffar, Umar
    Kim, Isaac Y.
    Saperstein, Lawrence
    Wang, Shi-Yi
    Ma, Xiaomei
    Gross, Cary P.
    Leapman, Michael S.
    JOURNAL OF UROLOGY, 2024, 211 (05): : E940 - E941
  • [29] Proposal for a Structured Reporting System for Prostate-Specific Membrane Antigen-Targeted PET Imaging: PSMA-RADS Version 1.0
    Rowe, Steven P.
    Pienta, Kenneth J.
    Pomper, Martin G.
    Gorin, Michael A.
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (03) : 479 - 485
  • [30] PSMA-RADS in the assessment of 18F-DCFPyL (PSMA) PET/CT and its correlation with prostate-specific antigen values.
    Rivas-Navas, D.
    Trivino-Ibanez, E.
    Sanchez-Sanchez, R.
    Villa-Palacios, J.
    Rodriguez-Fernandez, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S531 - S532
12345